METROPOLIS HEALTHCARE LTD.
NSE : METROPOLISBSE : 542650ISIN
CODE : INE112L01020Industry : Hospital & Healthcare ServicesHouse
: Metropolis
BSE1847.454.95 (+0.27 % )
PREV CLOSE (Rs.) 1842.50
OPEN PRICE (Rs.) 1861.95
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 671
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE1844.00 5.8 (+0.32 % )
PREV CLOSE(Rs.) 1838.20
OPEN PRICE (Rs.) 1849.00
BID PRICE (QTY) 1844.00 (10 )
OFFER PRICE (QTY) 1847.00 (29 )
VOLUME 9883
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 16-May-2024 | Metropolis Healthcare informs about conference call | <div style="text-align: justify;">Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), Metropolis Healthcare has informed that the Company will participate in the Q4 FY24 earnings conference call (i.e. post earnings/quarterly call), organized by JM Financial Institutional Securities on Wednesday, May 22, 2024 at 09:00 am (IST) to discuss the financial results of the Company for the quarter ended March 31, 2024 as per details enclosed.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 14-May-2024 | Metropolis Healthcare informs about board meeting | <p style="text-align: justify;">Metropolis Healthcare has informed that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 21, 2024 to: consider and approve the Audited Standalone & Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2024. In terms of the Company's Code of Fair Disclosure of Unpublished Price Sensitive Information, the Trading Window for dealing in the securities of the Company has been closed for the Designated Persons of the Company and their immediate relatives with effect from April 01, 2024 and shall re-open 48 hours after the declaration of the Financial Results of the Company for the quarter and financial year ended March 31, 2024, as intimated to the stock exchanges vide its letter MHL/Sec&Legal/2023-24/101 dated March 29, 2024. </p><div>The above information is a part of company's filings submitted to BSE.</div> |
| 30-Apr-2024 | Metropolis Healthcare informs about disclosure | <p style="text-align: justify;">Pursuant to Regulation 30 of the Listing Regulations and in continuation to itsletter dated August 14, 2023, Metropolis Healthcare has informed that the suit filed by Metropolis Bramser Lab Services (Mtius) (‘Metropolis Bramser', step-down WOS of the Company) before the Supreme Court of Mauritius has been dismissed. The details as required under SEBI Circular No SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13 July 2023 are enclosed.</p><div>The above information is a part of company's filings submitted to BSE.</div> |
| 15-Apr-2024 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | Intimation of allotment of equity shares under Metropolis Healthcare Limited Restrictive Stock Unit Plan -2020 |
| 12-Apr-2024 | Metropolis Healthcare reports 15% growth in core business revenue during Q4FY24 | <p style="text-align: justify;">Metropolis Healthcare has reported around 15% growth Year-on-Year (Y-o-Y) in core business revenue during fourth quarter of FY24. Its core revenue growth was driven by volume growth around 8% and Revenue Per Patient (RPP) growth at 7% YoY for Q4FY24. RPP growth was largely driven by growth in speciality tests segment, premium wellness segment and price increase. The company's Business-to-Consumer (B2C) revenue grew at around 18% Y-o-Y for Q4FY24. Meanwhile, the company has become debt-free in Q4FY24. </p><p style="text-align: justify;">Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services.</p> |
| 12-Apr-2024 | Metropolis Healthcare soars on reporting 15% growth in core business revenue during Q4FY24 | <p style="text-align: justify;">Metropolis Healthcare is currently trading at Rs. 1883.30, up by 83.95 points or 4.67% from its previous closing of Rs. 1799.35 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 1864.00 and has touched a high and low of Rs. 1935.00 and Rs. 1850.55 respectively. So far 267666 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,935.00 on 12-Apr-2024 and a 52 week low of Rs. 1209.25 on 22-May-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 1935.00 and Rs. 1679.30 respectively. The current market cap of the company is Rs. 9647.55 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 49.74%, while Institutions and Non-Institutions held 42.39% and 7.87% respectively.</p><p style="text-align: justify;">Metropolis Healthcare has reported around 15% growth Year-on-Year (Y-o-Y) in core business revenue during fourth quarter of FY24. Its core revenue growth was driven by volume growth around 8% and Revenue Per Patient (RPP) growth at 7% YoY for Q4FY24. RPP growth was largely driven by growth in speciality tests segment, premium wellness segment and price increase. The company's Business-to-Consumer (B2C) revenue grew at around 18% Y-o-Y for Q4FY24. Meanwhile, the company has become debt-free in Q4FY24. </p><p style="text-align: justify;">Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services.</p> |
| 14-Mar-2024 | Metropolis Healthcare informs about disclosure | <div style="text-align: justify;">Metropolis Healthcare has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund & Others.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE. </div> |
| 05-Mar-2024 | Metropolis Healthcare informs about disclosure | <div>Pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular No SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13 July 2023, Metropolis Healthcare has informed that it submitted a disclosure in Annexure A.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 29-Feb-2024 | Metropolis Healthcare informs about disclosure | <p style="text-align: justify;">Pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular No SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13 July 2023, Metropolis Healthcare has informed that it enclosed details in the requisite format. </p><div>The above information is a part of company's filings submitted to BSE.</div> |
| 15-Feb-2024 | Appointment of Director | Inter alia, approved:- i. Accepted and took note of cessation of Ms. Neha Shah from the post of ?Interim Company Secretary and Compliance Officer? of the Company w.e.f. February 03, 2024. ii. Approved the Appointment of Mr. Kamlesh Kulkarni as ?Company Secretary & Compliance Officer? of the Company w.e.f. February 03, 2024. ii.Approved the appointment of Mr. Avadhut Joshi as ?Chief Business Development Officer?, as part of Senior Management Personnel w.e.f. February 02, 2024. iii.Approved the elevation of Mr. Umesh Rai from ?Head Digital Marketing? to ?Head Emerging Business?, as part of Senior Management Personnel w.e.f. February 02, 2024. |
